348 related articles for article (PubMed ID: 35072571)
1. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
Shibata Y; Murakami S
Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
[TBL] [Abstract][Full Text] [Related]
3. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
8. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
10. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab.
Abe H; Endo K; Kuroda H; Oikawa T; Abe T; Ito A; Suzuki A; Yoshida Y; Kakisaka K; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):307-310. PubMed ID: 38185741
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
17. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
[TBL] [Abstract][Full Text] [Related]
18. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
19. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
20. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
